123 related articles for article (PubMed ID: 38185054)
21. Two novel camptothecin derivatives inhibit colorectal cancer proliferation via induction of cell cycle arrest and apoptosis in vitro and in vivo.
Du H; Huang Y; Hou X; Quan X; Jiang J; Wei X; Liu Y; Li H; Wang P; Zhan M; Ai X; Lu L; Yuan S; Sun L
Eur J Pharm Sci; 2018 Oct; 123():546-559. PubMed ID: 30118848
[TBL] [Abstract][Full Text] [Related]
22. A novel DNA topoisomerase I inhibitor with different mechanism from camptothecin induces G2/M phase cell cycle arrest to K562 cells.
Wu N; Wu XW; Agama K; Pommier Y; Du J; Li D; Gu LQ; Huang ZS; An LK
Biochemistry; 2010 Nov; 49(47):10131-6. PubMed ID: 21033700
[TBL] [Abstract][Full Text] [Related]
23. Inactivation of p53 increases the cytotoxicity of camptothecin in human colon HCT116 and breast MCF-7 cancer cells.
Gupta M; Fan S; Zhan Q; Kohn KW; O'Connor PM; Pommier Y
Clin Cancer Res; 1997 Sep; 3(9):1653-60. PubMed ID: 9815856
[TBL] [Abstract][Full Text] [Related]
24. New Topoisomerase I mutations are associated with resistance to camptothecin.
Gongora C; Vezzio-Vie N; Tuduri S; Denis V; Causse A; Auzanneau C; Collod-Beroud G; Coquelle A; Pasero P; Pourquier P; Martineau P; Del Rio M
Mol Cancer; 2011 May; 10():64. PubMed ID: 21619602
[TBL] [Abstract][Full Text] [Related]
25. Design, synthesis and antitumor activity of non-camptothecin topoisomerase I inhibitors.
Zhang C; Li S; Ji L; Liu S; Li Z; Li S; Meng X
Bioorg Med Chem Lett; 2015 Oct; 25(20):4693-6. PubMed ID: 26384290
[TBL] [Abstract][Full Text] [Related]
26. Camptothecin resistance from a single mutation changing glycine 363 of human DNA topoisomerase I to cysteine.
Benedetti P; Fiorani P; Capuani L; Wang JC
Cancer Res; 1993 Sep; 53(18):4343-8. PubMed ID: 8395982
[TBL] [Abstract][Full Text] [Related]
27. Homocamptothecin, an E-ring-modified camptothecin analogue, generates new topoisomerase I-mediated DNA breaks.
Bailly C; Lansiaux A; Dassonneville L; Demarquay D; Coulomb H; Huchet M; Lavergne O; Bigg DC
Biochemistry; 1999 Nov; 38(47):15556-63. PubMed ID: 10569939
[TBL] [Abstract][Full Text] [Related]
28. Anti-tumor effects and mechanism of a novel camptothecin derivative YCJ100.
Zhang M; Fu W; Zhu LZ; Liu XF; Li L; Peng LZ; Kai GY; Liu YQ; Zhang ZJ; Xu CR
Life Sci; 2022 Dec; 311(Pt A):121105. PubMed ID: 36272467
[TBL] [Abstract][Full Text] [Related]
29. Identification of Leishmania donovani Topoisomerase 1 inhibitors via intuitive scaffold hopping and bioisosteric modification of known Top 1 inhibitors.
Mamidala R; Majumdar P; Jha KK; Bathula C; Agarwal R; Chary MT; Majumder HK; Munshi P; Sen S
Sci Rep; 2016 May; 6():26603. PubMed ID: 27221589
[TBL] [Abstract][Full Text] [Related]
30. Novel diindoloazepinone derivatives as DNA minor groove binding agents with selective topoisomerase I inhibition: Design, synthesis, biological evaluation and docking studies.
Kadagathur M; Devi GP; Grewal P; Sigalapalli DK; Makhal PN; Banerjee UC; Bathini NB; Tangellamudi ND
Bioorg Chem; 2020 Jun; 99():103629. PubMed ID: 32272367
[TBL] [Abstract][Full Text] [Related]
31. Phenylpyrazolo[1,5-a]quinazolin-5(4H)-one: a suitable scaffold for the development of noncamptothecin topoisomerase I (Top1) inhibitors.
Taliani S; Pugliesi I; Barresi E; Salerno S; Marchand C; Agama K; Simorini F; La Motta C; Marini AM; Di Leva FS; Marinelli L; Cosconati S; Novellino E; Pommier Y; Di Santo R; Da Settimo F
J Med Chem; 2013 Sep; 56(18):7458-62. PubMed ID: 23987476
[TBL] [Abstract][Full Text] [Related]
32. Design, synthesis and evaluation of 4-substituted anthra[2,1-c][1,2,5]thiadiazole-6,11-dione derivatives as novel non-camptothecin topoisomerase I inhibitors.
Dong G; Fang Y; Liu Y; Liu N; Wu S; Zhang W; Sheng C
Bioorg Med Chem Lett; 2017 May; 27(9):1929-1933. PubMed ID: 28351590
[TBL] [Abstract][Full Text] [Related]
33. Three missense mutations of DNA topoisomerase I in highly camptothecin-resistant colon cancer cell sublines.
Arakawa Y; Ozaki K; Okawa Y; Yamada H
Oncol Rep; 2013 Sep; 30(3):1053-8. PubMed ID: 23836376
[TBL] [Abstract][Full Text] [Related]
34. Molecular mechanism of the camptothecin resistance of Glu710Gly topoisomerase IB mutant analyzed in vitro and in silico.
Tesauro C; Morozzo della Rocca B; Ottaviani A; Coletta A; Zuccaro L; Arnò B; D'Annessa I; Fiorani P; Desideri A
Mol Cancer; 2013 Sep; 12(1):100. PubMed ID: 24004603
[TBL] [Abstract][Full Text] [Related]
35. Novel 7-alkyl methylenedioxy-camptothecin derivatives exhibit increased cytotoxicity and induce persistent cleavable complexes both with purified mammalian topoisomerase I and in human colon carcinoma SW620 cells.
Valenti M; Nieves-Neira W; Kohlhagen G; Kohn KW; Wall ME; Wani MC; Pommier Y
Mol Pharmacol; 1997 Jul; 52(1):82-7. PubMed ID: 9224816
[TBL] [Abstract][Full Text] [Related]
36. Differential induction of Leishmania donovani bi-subunit topoisomerase I-DNA cleavage complex by selected flavones and camptothecin: activity of flavones against camptothecin-resistant topoisomerase I.
Das BB; Sen N; Roy A; Dasgupta SB; Ganguly A; Mohanta BC; Dinda B; Majumder HK
Nucleic Acids Res; 2006; 34(4):1121-32. PubMed ID: 16488884
[TBL] [Abstract][Full Text] [Related]
37. Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials.
Tanizawa A; Fujimori A; Fujimori Y; Pommier Y
J Natl Cancer Inst; 1994 Jun; 86(11):836-42. PubMed ID: 8182764
[TBL] [Abstract][Full Text] [Related]
38. Camptothecin conjugated with DNA minor-groove binder netropsin: enhanced lactone stability, inhibition of human DNA topoisomerase I and antiproliferative activity.
Sukhanova A; Grokhovsky S; Zhuze A; Devy J; Pluot M; Oleinikov V; Nabiev I
Anticancer Res; 2003; 23(3B):2609-15. PubMed ID: 12894548
[TBL] [Abstract][Full Text] [Related]
39. Characterization of ARC-111 as a novel topoisomerase I-targeting anticancer drug.
Li TK; Houghton PJ; Desai SD; Daroui P; Liu AA; Hars ES; Ruchelman AL; LaVoie EJ; Liu LF
Cancer Res; 2003 Dec; 63(23):8400-7. PubMed ID: 14679002
[TBL] [Abstract][Full Text] [Related]
40. Synthesis, cytotoxicity and structure-activity relationship of indolizinoquinolinedione derivatives as DNA topoisomerase IB catalytic inhibitors.
Yu Q; Yang H; Zhu TW; Yu LM; Chen JW; Gu LQ; Huang ZS; An LK
Eur J Med Chem; 2018 May; 152():195-207. PubMed ID: 29705710
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
